Solara Active Pharma Sciences Ltd
P&L
Quarterly Consolidated
vs Q3 FY25
Solara Active Pharma Sciences Ltd Reports Q4 FY25 Performance with Flat YoY Revenue and Significant Improvement in Gross Margin and EBITDA
15 May 2025 · 15 May 2025, 04:57 pm
Summary
Solara Active Pharma Sciences Ltd has reported its Q4 FY25 performance. The company's revenue was flat YoY, but it saw a significant improvement in gross margin and EBITDA. The improvement is attributed to the company's focus on margin expansion. However, there was a significant miss on revenue and EBITDA guidance due to intense competition on Ibuprofen range of products.
Key Highlights
- 1
Q4 FY25 Revenues at INR 2,790 Mn
- 2
Q4 Gross Margin at INR 1,605 Mn (57.5%)
- 3
Q4 EBITDA at INR 510 Mn (18.3%)
- 4
FY25 Revenues at INR 12,921 Mn vs INR 12,943 Mn in FY24 (flat YoY)
- 5
FY25 Gross Margin at INR 6,649 Mn (51.5%) vs INR 4,891 Mn (37.8%) in FY24 (improvement by 1,370 bps YoY)
- 6
FY25 EBITDA at INR 2,138 Mn (16.5%) vs. negative INR 917 Mn (-7%) in FY24 (significant improvement by 2,360 bps YoY)
- 7
Q4 FY25 Results | May 15, 2025
- 8
Solara continues to deliver on margin expansion & maintains stellar compliance track record
- 9
Q4’25 Gross Margin at INR 1,605 Mn (57.5%) vs INR 1,412 Mn (47%) in Q4’24 (significant improvement by 1,063 bps YoY)
- 10
FY25 Gross Margin at INR 6,649 Mn (51.5%) vs INR 4,891 Mn (38%) in FY24 (significant improvement by 1,370 bps YoY)
- 11
Q4’25 EBITDA at INR 510 Mn (18.3%) vs INR 112 Mn (4%) in Q4’24 (significant improvement by 1,458 bps YoY)
- 12
FY25 EBITDA at INR 2,138 Mn (16.5%) vs INR -917 Mn (-7%) in FY24 (significant improvement by 2,360 bps YoY)
- 13
Gross Debt as on 31-Mar-25 at INR 7,760 Mn vs INR 9,994 Mn in FY24 (reduced by INR 2,234 Mn YoY)
Management Comments
Sandeep Rao
MD & CEO
FY25 was a Reset year for Solara. While we regrettably missed our guidance both on Revenues and EBITDA, we continued to focus on profitable high margin and high quality business which led to Gross Margin expansion from 37.8% in FY24 to 51.5% in FY25 and EBITDA margin expansion from -7.1% in FY24 to 16.5% in FY25. The miss on the Revenue and EBITDA guidance is attributable to intense competition on the Ibuprofen range of products. We continued to do better than expected on the remainder of our portfolio. Our product mix continues to be healthy with a majority of Revenues coming from the Regulated markets. Going ahead, we will continue our ongoing actions on improving profitability through cost improvement programs, operating cost optimization, optimizing working capital and debt as we pivot the organization from reset to growth.
Informational and educational content only. Not investment advice.